Cirrus Pharmaceuticals to invest in cGMP manufacturing suite in US
Will offer services for dosage forms including inhalation, liquids, topicals and oral solids
Cirrus Pharmaceuticals, a Kemwell company which provides contract development and manufacturing services for the pharmaceutical industry, is investing in a cGMP suite at its facility in Research Triangle Park (RTP), North Carolina, US.
With this investment, the company will be able for the first time to offer cGMP manufacturing services for dosage forms including inhalation, liquids, topicals and oral solids from its US facility.
According to Ninad Deshpanday, President of R&D at Bangalore, India-based CDMO Kemwell, the design phase has been completed and the suite should be ready to service customers by April 2015.
Kemwell’s R&D division currently employs more than 175 scientists worldwide and provides services ranging from formulation development, analytical development and validation to clinical trial manufacturing.
The team has experience working on early stage development programs for NCEs, ANDAs, 505(b)(2) and product life cycle management projects for various customers across the world.
Cirrus was acquired by Kemwell in 2013.
